Cologne, Germany
BioEcho Life Sciences, founded in 2016, is poised at the forefront of biotechnology and healthcare innovation. Headquartered in Germany, this company specializes in the extraction and analysis of nucleic acids through disruptive technologies like their EchoLUTION system, noted for delivering unparalleled speed in DNA and RNA extraction.
The company's unique approach not only enhances throughput but also significantly reduces plastic consumption by up to 70%, appealing to both ecological and efficiency-driven customers within molecular diagnostics, academic research, and biopharmaceutical sectors. Notably, during the COVID-19 pandemic, their Viral RNA/DNA Swab kit was vital in up to 15% of Germany's and 50% of Austria's PCR tests.
Backed by Ampersand Capital Partners through a Private Equity Round in March 2022, BioEcho Life Sciences continues to expand its influence, leveraging a robust European sales team and a global distributor network. With ISO 9001 and ISO 13485 certifications, the company embodies reliability and innovation in the biotech industry.
